Download PDF
Thorac Cardiovasc Surg 2024; 72(03): 205-213
DOI: 10.1055/s-0041-1740539
Original Cardiovascular

Decellularized Pulmonary Xenograft Matrix PplusN versus Cryopreserved Homograft for RVOT Reconstruction during Ross Procedure in Adults

Kiril Penov 
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
,
Matz Andreas Haugen
2   Independent Researcher, Olso, Norway
,
Dejan Radakovic
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
,
Khaled Hamouda
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
,
Armin Gorski
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
,
Rainer Leyh
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
,
Constanze Bening
1   Department of Thoracic and Cardiovascular Surgery, University Clinic Würzburg, Julius Maximilians University Würzburg, Würzburg, Bayern, Germany
› Author Affiliations
› Further Information
    Permissions and Reprints All articles of this category

Abstract

Background Decellularized pulmonary homografts are being increasingly adopted for right ventricular outflow tract reconstruction in adult patients undergoing the Ross procedure. Few reports presented Matrix PplusN xenograft (Matrix) in a negative light. The objective of this study was to compare our midterm outcomes of Matrix xenograft versus standard cryopreserved pulmonary homograft (CPHG).

Methods Eighteen patients received Matrix xenograft between January 2012 and June 2016, whereas 66 patients received CPHG. Using nonparametric statistical tests and survival analysis, we compared midterm echocardiographic and clinical outcomes between the groups.

Results Except for significant age difference (the Matrix group was significantly older with 57 ± 8 years than the CPHG group, 48 ± 9 years, p = 0.02), the groups were similar in all other baseline characteristics. There were no significant differences in cardiopulmonary bypass times (208.3 ± 32.1 vs. 202.8 ± 34.8) or in cross-clamp times (174 ± 33.9 vs. 184.4 ± 31.1) for Matrix and CPHG, respectively. The Matrix group had significantly inferior freedom from reintervention than the CPHG group with 77.8 versus 98.5% (p = 0.02). Freedom from pulmonary valve regurgitation ≥ 2 was not significantly different between the groups with 82.4 versus 90.5% for Matrix versus CPHG, respectively. After median follow-up of 4.9 years, Matrix xenograft developed significantly higher peak pressure gradients compared with CPHG (20.4 ± 15.5 vs. 12.2 ± 9.0 mm Hg; p = 0.04).

Conclusion After 5 years of clinical and echocardiographic follow-up, the decellularized Matrix xenograft had inferior freedom from reintervention compared with the standard CPHG. Closer follow-up is necessary to avoid progression of valve failure into right ventricular deterioration.

Keywords

pulmonary valve - echocardiography (all modalities, applications) - heart valve surgery - outcomes (includes mortality, morbidity)


Publication History

Received: 01 June 2021

Accepted: 20 September 2021

Article published online:
31 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mazine A, Rocha RV, El-Hamamsy I. et al. Ross procedure vs mechanical aortic valve replacement in adults: a systematic review and meta-analysis. JAMA Cardiol 2018; 3 (10) 978-987
    Google Scholar
  • 2 Poh CL, Buratto E, Larobina M. et al. The Ross procedure in adults presenting with bicuspid aortic valve and pure aortic regurgitation: 85% freedom from reoperation at 20 years. Eur J Cardiothorac Surg 2018; 54 (03) 420-426
    Google Scholar
  • 3 Martin E, Mohammadi S, Jacques F. et al. Clinical outcomes following the Ross procedure in adults: a 25-year longitudinal study. J Am Coll Cardiol 2017; 70 (15) 1890-1899
    Google Scholar
  • 4 Doenst T, Bargenda S, Kirov H. et al. Cardiac surgery 2019 reviewed. Thorac Cardiovasc Surg 2020; 68 (05) 363-376
    Google Scholar
  • 5 Etnel JRG, Grashuis P, Huygens SA. et al. The Ross procedure: a systematic review, meta-analysis, and microsimulation. Circ Cardiovasc Qual Outcomes 2018; 11 (12) e004748
    Google Scholar
  • 6 Sievers HH, Stierle U, Charitos EI. et al; German-Dutch Ross Registry. Major adverse cardiac and cerebrovascular events after the Ross procedure: a report from the German-Dutch Ross Registry. Circulation 2010; 122 (11, Suppl): S216-S223
    Google Scholar
  • 7 Schaff HV. Ross procedure for aortic valve replacement in young adults: preferred procedure or “double, double toil and trouble”?. Circulation 2016; 134 (08) 586-588
    Google Scholar
  • 8 Charitos EI, Takkenberg JJ, Hanke T. et al. Reoperations on the pulmonary autograft and pulmonary homograft after the Ross procedure: an update on the German Dutch Ross Registry. J Thorac Cardiovasc Surg 2012; 144 (04) 813-821 , discussion 821–823
    Google Scholar
  • 9 Perry GJ, Helmcke F, Nanda NC. et al. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987
    Google Scholar
  • 10 Mokhles MM, Charitos EI, Stierle U. et al. The fate of pulmonary conduits after the Ross procedure: longitudinal analysis of the German-Dutch Ross registry experience. Heart 2013; 99 (24) 1857-1866
    Google Scholar
  • 11 Etnel JRG, Suss PH, Schnorr GM. et al. Fresh decellularized versus standard cryopreserved pulmonary allografts for right ventricular outflow tract reconstruction during the Ross procedure: a propensity-matched study. Eur J Cardiothorac Surg 2018; 54 (03) 434-440
    Google Scholar
  • 12 Chauvette V, Bouhout I, Tarabzoni M. et al; Canadian Ross Registry. Pulmonary homograft dysfunction after the Ross procedure using decellularized homografts-a multicenter study. J Thorac Cardiovasc Surg 2022; 163 (04) 1296-1305.e3
    Google Scholar
  • 13 Liebrich M, Hemmer W, Uhlemann F. et al. A novel designed valved conduit for RVOT reconstruction in grown-up congenital heart patients: a glimpse down the road. Thorac Cardiovasc Surg 2016; 64 (01) 36-43
    Google Scholar
  • 14 Boethig D, Westhoff-Bleck M, Hecker H. et al. Bovine jugular veins in the pulmonary position in adults – 5 years' experience with 64 implantations. Thorac Cardiovasc Surg 2009; 57 (04) 196-201
    Google Scholar
  • 15 Dohmen PM, Lembcke A, Holinski S. et al. Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg 2007; 84 (03) 729-736
    Google Scholar
  • 16 Bechtel JF, Gellissen J, Erasmi AW. et al. Mid-term findings on echocardiography and computed tomography after RVOT-reconstruction: comparison of decellularized (SynerGraft) and conventional allografts. Eur J Cardiothorac Surg 2005; 27 (03) 410-415 , discussion 415
    Google Scholar
  • 17 Purohit M, Kitchiner D, Pozzi M. Contegra bovine jugular vein right ventricle to pulmonary artery conduit in Ross procedure. Ann Thorac Surg 2004; 77 (05) 1707-1710
    Google Scholar
  • 18 Marianeschi SM, Iacona GM, Seddio F. et al. Shelhigh no-react porcine pulmonic valve conduit: a new alternative to the homograft. Ann Thorac Surg 2001; 71 (02) 619-623
    Google Scholar
  • 19 Rüffer A, Purbojo A, Cicha I. et al. Early failure of xenogenous de-cellularised pulmonary valve conduits–a word of caution!. Eur J Cardiothorac Surg 2010; 38 (01) 78-85
    Google Scholar
  • 20 Voges I, Bräsen JH, Entenmann A. et al. Adverse results of a decellularized tissue-engineered pulmonary valve in humans assessed with magnetic resonance imaging. Eur J Cardiothorac Surg 2013; 44 (04) e272-e279
    Google Scholar
  • 21 Christ T, Paun AC, Grubitzsch H, Holinski S, Falk V, Dushe S. Long-term results after the Ross procedure with the decellularized AutoTissue Matrix P® bioprosthesis used for pulmonary valve replacement. Eur J Cardiothorac Surg 2019; 55 (05) 885-892
    Google Scholar
  • 22 Hiemann NE, Mani M, Huebler M. et al. Complete destruction of a tissue-engineered porcine xenograft in pulmonary valve position after the Ross procedure. J Thorac Cardiovasc Surg 2010; 139 (04) e67-e68
    Google Scholar
  • 23 Konertz W, Dohmen PM, Liu J. et al. Hemodynamic characteristics of the Matrix P decellularized xenograft for pulmonary valve replacement during the Ross operation. J Heart Valve Dis 2005; 14 (01) 78-81
    Google Scholar
  • 24 Buckberg GD. Strategies and logic of cardioplegic delivery to prevent, avoid, and reverse ischemic and reperfusion damage. J Thorac Cardiovasc Surg 1987; 93 (01) 127-139
    Google Scholar
  • 25 da Costa FDA, Etnel JRG, Charitos EI. et al. Decellularized versus standard pulmonary allografts in the Ross procedure: propensity-matched analysis. Ann Thorac Surg 2018; 105 (04) 1205-1213
    Google Scholar
  • 26 Nordmeyer J, Lurz P, Tsang VT. et al. Effective transcatheter valve implantation after pulmonary homograft failure: a new perspective on the Ross operation. J Thorac Cardiovasc Surg 2009; 138 (01) 84-88
    Google Scholar
  • 27 Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008; 117 (11) 1436-1448
    Google Scholar
  • 28 Fathallah M, Krasuski RA. Pulmonic valve disease: review of pathology and current treatment options. Curr Cardiol Rep 2017; 19 (11) 108
    Google Scholar
  • 29 Engle MA, Holswade GR, Goldberg HP, Lukas DS, Glenn F. Regression after open valvotomy of infundibular stenosis accompanying severe valvular pulmonic stenosis. Circulation 1958; 17 (05) 862-873
    Google Scholar
  • 30 Tulevski II, Hirsch A, Dodge-Khatami A, Stoker J, van der Wall EE, Mulder BJ. Effect of pulmonary valve regurgitation on right ventricular function in patients with chronic right ventricular pressure overload. Am J Cardiol 2003; 92 (01) 113-116
    Google Scholar